These insights suggest that TP53 status may serve not only as a prognostic marker but also as a potential determinant of immunotherapy responsiveness, warranting further investigation into p53-guided therapeutic strategies in ovarian cancer. This evidence concerns the gene TP53 and ovarian carcinoma.